Dermal blood vessels and regional lymph nodes are innervated by sympathetic nerves and, under stress, sympathetic nerves release norepinephrine (NE). Exposure of primary murine dermal microvascular endothelial cells (pDMECs) to NE followed by co-culture with Langerhans cells ( 
Introduction
It has long been believed that neurological status and emotional state influence the expression of inflammatory skin disorders, including seborrheic dermatitis, atopic dermatitis and psoriasis, [1] [2] [3] among others. In this regard, stress has been shown to have a number of regulatory effects on immunological processes in humans and animals. Neuroendocrine pathways appear to mediate at least some of these effects. In animal models, stress exacerbates an atopic dermatitis-like rash in a murine model, 4 induces mast cell degranulation in mice and rats 5, 6 and leads to enhanced mast cell content of the skin in rats. 7 In this regard, we have previously reported that certain products of nerves can influence the function of epidermal antigen-presenting cells (APCs), [8] [9] [10] and the outcome of some immune processes in vitro and in vivo. The relevance of nervous system influences on inflammatory skin Abbreviations: APC, antigen-presenting cell; AR, adrenergic receptor; ATP, adenosine triphosphate; CGRP, calcitonin generelated peptide; CM, complete medium; cOVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] , chicken ovalbumin peptide 323-339; DNFB, 1-chloro-2,4-dinitrobenzene; EC, endothelial cell; EGF, epidermal growth factor; EPI, epinephrine; FACS, fluorescent antibody cell sorting; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; GATA3, trans-acting T-cell-specific transcription factor; IFN, interferon; IL, interleukin; LC, Langerhans cell; NE, norepinephrine; PBS, phosphate-buffered saline; pDMEC, primary dermal microvascular endothelial cell; PE, phycoerythrin; PerCP, peridinin chlorophyll; ROR-c, retinoic acid receptor-related orphan receptor gamma; RT 
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disease is demonstrated by the observation that denervation of skin leads to clearing of psoriasis, 11, 12 and at least two models of psoriasiform dermatitis in mice also require innervation for their phenotypical expression. 13, 14 Endothelial cells (ECs) have important inflammatory and immunological functions by regulating the transit of immune and inflammatory cells in and out of the vasculature and by production of inflammatory mediators, both peptides and non-peptide factors. [15] [16] [17] [18] [19] In this regard, both blood vessels in the skin and secondary lymphoid organs are innervated by sensory and sympathetic nerves. [20] [21] [22] We have previously reported that the sympathetic nerve neurotransmitters adenosine triphosphate (ATP) and norepinephrine (NE) are capable of inducing the release of certain chemokines and cytokines by microvascular ECs. ATP induces production of interleukin (IL)-6, C-X-C motif chemokine ligand (CXCL)1, CXCL8 and C-C motif chemokine ligand (CCL)2, 23, 24 and NE and ATP synergize in inducing IL-6 release by human microvascular ECs. 25 We have also found that the peptide neurotransmitter calcitonin gene-related peptide (CGRP) inhibits production of the chemokines CXCL1, CXCL8 and CCL2 by human dermal microvascular ECs stimulated by lipopolysaccharide (LPS). 26 Of particular interest, we have also recently demonstrated that CGRP can polarize the outcome of presentation of antigen by epidermal Langerhans cells (LCs) to CD4 + T-cells towards an IL-17A/T helper type 17A (Th17) response and away from a Th1 response through actions on dermal microvascular ECs acting as bystanders. 27 This effect does not require contact between CGRP-treated ECs and either LCs or responding T-cells.
As mentioned above, innervation is required for expression of human psoriasis and psoriasiform dermatitis in certain mouse models. In this regard, as stress appears to worsen psoriasis, the possibility that release of sympathetic neurotransmitters under conditions of stress may relate to this phenomenon could be considered. We have now examined the possibility that NE may regulate relevant immune processes through actions on ECs.
Lymphocytes and APCs exiting dermal blood vessels are closely associated with ECs during this process. Additionally, APCs and T-cells often are present in a perivascular distribution in inflammatory skin disorders where they may interact. Release of EC-derived factors on the abluminal side of vessels would be spatially situated to interact with these cells. The function of ECs within lymph nodes may also be modulated by NE derived from sensory nerves, and these ECs would be able to interact with immune cells in the lymph node. Thus, we have now examined the ability of NE to modulate the outcome of antigen presentation by LCs to CD4 + T-cells. LCs, depending on the situation, can present antigen for induction or regulation of various immune responses. 28, 29 We have elected to examine LCs, as their function has been demonstrated previously to be modulated by neuropeptides.
9,10,30-34 Furthermore, they have been shown to traffic through lymphatics to regional lymph nodes after encountering antigen. Also relevant to this study, LCs have been shown to present antigen for generation of Th17 helper T-cells that appear to be involved in the pathophysiology of a number of inflammatory skin diseases including psoriasis. 35, 36 and neuroendocrine regulation of immunity has been well-described. 37, 38 We discovered that NE alters the outcome of antigen presentation through effects on ECs acting as bystanders. Although most of the experiments presented were performed in vitro, the co-culture systems employed in which LCs, CD4 + T-cells and ECs are cultured together may provide an environment perhaps similar to that in the lymph nodes or dermis during immune activities at those sites.
Material and methods

Animals
Six-to 12-week-old female BALB/c (H-2 d ) and DO11.10 chicken ovalbumin (cOVA) T-cell receptor (TCR) transgenic mice on a BALB/c background [C.Cg-Tg(DO11.10) 10Dlo/J] mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained in a controlled environment on a 12-hr light/dark cycle with ad libitum access to food and water. The DO11.10 transgenic mice carry major histocompatibility complex (MHC) class IIrestricted, rearranged TCR-a and -b chain genes that encode a TCR that recognizes a fragment of cOVA (cOVA 323-339 ) presented by I-A d . 39, 40 All animal studies were approved by the Institutional Animal Care and Use Committee of the Weill Cornell Medical College (Protocol number 2013-0120).
and DNFB (1-chloro-2.4-dinitrobenzene) were purchased from Millipore Sigma (St Louis, MO). A fragment of cOVA (cOVA 323-339 ) was purchased from Peptides International (Louisville, KY). Anti-mouse CD3 and antimouse CD28 monoclonal antibodies were purchased from BD Biosciences (San Jose, CA).
Media and cell lines
Complete medium (CM) consisted of RPMI-1640 (Mediatech, Manassas, VA), 10% fetal bovine serum (FBS) [American Type Culture Collection (ATCC), Manassas, VA], 100 U/ml penicillin, 100 lg/ml streptomycin, 0Á1 mM non-essential amino acids, 0Á1 mM essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 10 mM HEPES buffer (all from Mediatech).
pDMECs from BALB/c mice were obtained from Cell Biologics (Chicago, IL) and were maintained in complete endothelial cell medium consisting of basal endothelial medium supplemented with vascular endothelial growth factor (VEGF), heparin, endothelial growth factor (EGF), EC growth supplement, hydrocortisone, L-glutamine, antibiotic-anti-mycotic solution and 10% FBS (endothelial basal medium and supplement kits from Cell Biologics). ECs derived from brachial and inguinal lymph nodes of BALB/c mice were prepared by and obtained from Cell Biologic. They were reported by the company to be > 95% ECs. ECs were maintained in depleted EC medium (consisting of EBM-2 medium with 5% FBS and L-glutamine) overnight before experiments were performed.
The brain-derived BALB/c endothelial cell line bEnd.3 was obtained from the ATCC. These cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS and 1% penicillin/streptomycin.
Preparation of LCs
Epidermal cells were prepared using a modification of a standard protocol. 9 Briefly, truncal skins of mice were shaved with electric clippers and chemically depilated. Subcutaneous fat and panniculus carnosus were removed by blunt dissection. Skin was floated dermisside down for 45 min in Ca 2+ /Mg 2+ -free phosphate-buffered saline (PBS) containing 0Á5 U/ml of dispase (BD Biosciences) and 0Á38% trypsin (Mediatech). Epidermal sheets were collected by gentle scraping, washed and dissociated by repetitive pipetting in Hanks's balanced salt solution (HBSS) (Mediatech) supplemented with 2% FBS (ATCC). ECs were filtered through a 40-lm cell strainer (BD Biosciences) to yield ECs containing 2-3% LCs.
Epidermal cells were incubated with anti-I-A d monoclonal antibody (mAb) (BD Biosciences) (5 lg/ml) for 30 min at 4°. They were then incubated with goat antimouse immunoglobulin (Ig)G conjugated to magnetic microspheres (Dynabeads M-450; Thermo Fisher Scientific, Carlsbad, CA) for 10 min with continuous, gentle agitation. LCs were isolated by placing the tube in a magnetic particle concentrator (BD Biosciences), discarding the supernatant and washing the bead-bound cells (up to five times) with HBSS containing 2% FBS. LCs isolated this way were approximately 95% pure by fluorescent antibody cell sorting (FACS) analysis.
Isolation of CD4
+ T-cells from DO11.10 transgenic mice DO11.10 transgenic mouse spleens were mechanically disrupted to yield a single-cell suspension and erythrocytes were lysed. CD4 + cells were isolated by depletion of nontarget cells. The non-target cells were indirectly magnetically labelled with a cocktail of biotin-conjugated monoclonal antibodies against CD8a, CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, anti-MHC class II, Ter-119, and TCR-c/d as primary labelling reagent, and anti-biotin monoclonal antibodies conjugated to microbeads as secondary labelling reagent (Miltenyi Biotec, Auburn, CA). The magnetically labelled non-target cells were on a MACS column in the magnetic field of a MACS separator, while the unlabelled CD4 + Tcells passed through the column (Miltenyi Biotec). By FACS, CD4 + cells were approximately 97% pure.
RNA interference
Ten thousand pDMECs per well were plated in 96-well round-bottomed plates (Corning Life Sciences, Tewksbury, MA) in antibiotic-free medium and incubated at 37°until adherence. The appropriate amount of ON-TARGET plus SMARTpool mouse IL-6 short interfering RNA (siRNA) (GE Dharmacon, Lafayette, CO) target sequences
0 ; and 5 0 -CUACCAAACUGGAUAUAAU-3 0 ) or the corresponding ON-TARGET plus non-targeting pool were diluted in OptiMEM medium (Thermo Fisher Scientific) to obtain a final concentration of 100 nM. Lipofectamine 2000 (Thermo Fisher Scientific) was also diluted following the manufacturer's instructions in OptiMEM. The diluted siRNA and lipofectamine 2000 were mixed and incubated for 20 min at room temperature for complex formation. Twenty-five ll complexed siRNA was added to each well. After overnight incubation at 37°, the medium was replaced with depleted EC medium for treatment with NE.
In-vitro antigen presentation to DO11.10 transgenic mouse T-cells
Ten thousand pDMECs/well were plated in 96-well, round-bottomed plates coated with 2% gelatin in depleted endothelial basal medium, then incubated overnight at 37°. The following day, cells were treated with a range of concentrations of NE, epinephrine (EPI) or medium alone for 3 hr at 37°. Cells were then washed extensively, and 1 9 10 4 LCs (from BALB/c mice) and 3 9 10 5 CD4 + T-cells (from DO11.10 transgenic mice) were added to each well in a total of 250 ll of CM containing 10 lM of cOVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] alone as above. Cells were then washed extensively, and 1Á25 9 10 4 purified LCs (from BALB/c mice) and 3Á75 9 10 5 purified CD4 + T-cells (from DO11.10 transgenic mice) in CM were added to the upper chamber in a total of 275 ll of medium containing 10 lM cOVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] . Supernatants were harvested 48 hr later and analysed for cytokine content.
Cytokine determinations
Supernatant IL-17A, IL-6, IL-4 and IL-22 levels were determined by sandwich ELISA following the manufacturer's instructions (R&D Systems, Minneapolis, MN). IL-22 ELISA kits were purchased from Antigenix America (Huntington Station, NY). IFN-c production in cultured medium was measured by a sandwich ELISA using purified rat antimouse IFN-c monoclonal capture antibodies, biotinylated rat anti-mouse IFN-c monoclonal detection antibodies, avidin-horseradish peroxidase (HRP) (BD Biosciences) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) substrate (BD Biosciences) read at 405 nm.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA from murine BALB/c primary dermal microvascular endothelial cells (pDMEC), ECs derived from brachial and inguinal lymph nodes or bEND.3 cells was extracted using a total RNA extraction kit as per the manufacturer's instructions (RNeasy total RNA Mini kit; Qiagen, Valencia, CA), including an additional DNA degradation step (RNase-free DNase set; Qiagen). BALB/c brain tissue total RNA was extracted using the RNeasy Plus Universal Mini kit (Qiagen), including an additional DNA degradation step (RNase-free DNase set; Qiagen).
The total RNA (1Á0 lg per 20 ll reaction) was reversetranscribed into complementary DNA with SuperScript TM IV VILO TM Master Mix (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. Four microliters of the complementary DNA were transferred to a PCR mixture containing 360 nM of each specific primer (IDT Technologies) and platinum PCR Supermix (Invitrogen) for a total reaction volume of 50 ll. All adrenergic receptor primers were designed from GenBank except those for a1 B and b 1 , which were selected from PrimerBank (http:// pga.mgh.harvard.edu/primerbank/). 0 for GAPDH. Denaturation for 2 min at 94°was followed by 39 cycles of denaturation for 30 seconds at 94°, annealing for 30 seconds at 55°and extension for 30 seconds at 72°r epeated with a thermal cycler (Gene Amp PCR System 9700; PerkinElmer), followed by completion for 2 min at 72°. The PCR product was gel-electrophoresed in 1% agarose, stained with ethidium bromide and visualized with ultraviolet (UV) radiation.
Glyceraldehyde 3-phosphate dehydrogenase (GADPH) control primers were obtained from IDT Technologies (Coralville, IA). Amplification of PCR product depended upon reverse transcription.
Real-time PCR
For gene expression analysis, CD4
+ T-cells from DO11.10 transgenic mice and LCs from BALB/c mice were co-cultured with NE-treated pDMECs in the presence of 10 lM OVA 323-339 for 24 hr. Non-adherent cells were gently collected from mixed culture wells after 24 hr incubation and LCs still bound to beads were removed by magnetic capture. Total RNA was isolated from the remaining cells (primarily CD4 + T-cells) using the RNeasy Plus Mini Kit (Qiagen); DNA eliminator columns were used to eliminate any contamination with genomic DNA. cDNA was synthesized using a high-capacity RNA-to-cDNA kit, according to the manufacturer's instructions (SuperScript VILO TM cDNA Synthesis Kit; Thermo Fisher Scientific). Real-time PCR for murine IL-17A (5 0 -GA . Pretreatment of pDMECs with NE resulted in a more potent response compared with EPI (***P < 0Á001, **P < 0Á01 for NE groups versus EPI groups). FACS pDMECs were treated with 10 À5 M NE or medium alone for 3 hr, washed four times and then co-cultured with LCs and CD4 + T-cells (from DO11.10 transgenic mice) in the presence of 10 lM cOVA 323-339 for 48 hr. For the last 5 hr of co-culture, cells were stimulated with 50 ng/ml phorbol myristate acetate (PMA) and 750 ng/ml ionomycin (Millipore Sigma). After 1 hr, GolgiStop (BD Biosciences) was added to block cytokine secretion. LCs still bound to beads were then removed by magnetic capture. CD4 + T-cells were surface-stained for 20-30 min at 4°with peridinin chlorophyll-cyanin 5Á5 (PerCP-Cy5Á5)-labelled anti-CD4 mAb (clone RM4-5) in PBS supplemented with 0Á1% bovine serum albumin (BSA) and 0Á1% sodium azide. After fixation and permeabilization with Cytofix/Cytoperm (BD Biosciences), cells were stained with Alexa Fluor 647-labelled anti-IL-17A (clone TC11-18H10); FITC-labelled anti-IFN-c (clone XMG1.2) and phycoerythrin (PE)-labelled anti-IL-4 (clone 11B11); all antibodies were purchased from BD Biosciences. Analysis was performed on a FACSCalibur (BD Biosciences). Data analysis was conducted using CellQuest Pro software (BD Biosciences).
Sensitization of mice to dinitrofluorobenzene (DNFB)
Mice were shaved on the dorsum with electric clippers, and 10 were injected intradermally on each side of the cranial dorsum with 100 ll of PBS containing 1 lg NE; 10 were injected in this manner with PBS alone for each experiment. Fifteen minutes after injection, half the mice in each group were painted epicutaneously with 10 ll of DNFB [1% in acetone:olive oil (4:1)] at each injected site and the other half were painted with vehicle alone at the injection site. After painting, each group (DNFB-or vehicle-treated) was divided into two groups of five.
Preparation of supernatants conditioned by CD4
+ T-cells stimulated with anti-CD3 and anti-CD28 Three days after immunization, mice were killed and draining lymph nodes (brachial, cervical and axillary) removed. Lymph nodes were mechanically disrupted and passed through a 70-lm nylon mesh to yield a single cell suspension. CD4
+ T-cells were isolated as described above. Ninety-six-well flat-bottomed plates were treated with 10 lg/ml of anti-mouse CD3 monoclonal antibody in PBS overnight and washed. T-cells were cultured (4 9 10 5 cells/well) in 250 ll of CM containing 2 lg/ml of anti-mouse CD28 monoclonal antibody in these plates. Supernatants were collected 72 hr after stimulation and cytokine contents were determined.
Biostatistics
Linear mixed-effects models were used to estimate the average level of each cytokine under different treatments. This model takes into account both within and betweenexperiment variations for each treatment. Log-transformation was applied to the cytokine level data to ensure that the underlying model assumption was satisfied. The difference in the average level of the cytokine under pairs of experimental conditions of interest was evaluated using simultaneous tests for general linear hypotheses. P-values were adjusted by controlling for the false discovery rate (FDR). The relative change in log-transformed levels of each gene between pairs of treatment groups were evaluated using one-sample t-test. P-values were adjusted for multiple comparisons by controlling the FDR. transgenic mice) were added along with 10 lM of chicken ovalbumin (cOVA) [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] . Forty-eight hr later supernatants were harvested and assessed for cytokine content using enzyme-linked immunosorbent assay (ELISA); n = 3 independent experiments for all groups, mean AE standard deviation (SD); ***P < 0Á001, **P < 0Á01, *P < 0Á05 compared to group with pDMECs but without NE-pretreatment. To determine whether NE-or EPI-exposed pDMECs may influence the outcome of LC antigen presentation to responsive T-cells, pDMECs were cultured in medium alone or medium containing NE or EPI for 3 hr. pDMECs were then extensively washed and co-cultured with LCs and CD4 + T-cells from DO11.10 transgenic mice along with cOVA 323-339 . Forty-eight hr later supernatants were harvested and assayed for cytokine content by ELISA. A significant increase in release of IL-17A (Fig. 1a) , IL-6 (Fig. 1b), IFN-c (Fig. 1c) and IL-22 ( Fig. 1d) was observed in the presence of medium-treated pDMECs accompanied by a small but significant decrease in IL-4 ( Fig. 1e) production. We compared the effect of NE and EPI on pDMECs in the same experiments; both NE and EPI had the ability to bias antigen presentation significantly towards IL-17A (Fig. 1a) and IL-6 (Fig. 1b) and significantly away from IFN-c (Fig. 1c) and IL-22 ( Fig. 1d) through action on ECs, but EPI was significantly less potent than NE, except on the IL-22 response (Fig. 1) . We conclude that both NE and EPI elicit a change in ECs that influences antigen presentation.
As NE was more potent than EPI and is the predominant catecholamine released by peripheral sympathetic nerves, subsequent experiments were performed with NE. A dose-response experiment with treatment of pDMECs with NE demonstrated a dose-dependent increase in the release of IL-17A (Fig. 2a) and IL-6 (Fig. 2b) , whereas the increase in IFN-c (Fig. 2c) and IL-22 production (Fig. 2d) was completely reversed while production of IL-4 was unchanged (Fig. 2e) .
pDMECs and lymph node-derived ECs express adrenergic receptors
As NE and EPI exert functional effects via actions on pDMECs, it would be expected that murine pDMECs would express adrenergic receptors. RT-PCR was Under the conditions of our experiment, we did not detect expression of the a 1A , a 2B or a 2C receptors (note that the positive control in the gel for a1a shows 2 bands being amplified. This was expected with this primer pair, as it is known that two transcript variants would be amplified 41 ). Results shown are all from the same representative gel except for a 1B , because the primers utilized were not available when the original experiments were performed, and a 2A for greater clarity; thus these two images were taken from different gels (denoted by dotted vertical lines). Each receptor examined is shown with the positive control and size markers. Receptor expression was verified with three separate RNA isolations for all receptors except a 1B , for which there were two determinations. Fig. 3b) a 1D (Fig. 3c), a 2A (Fig. 3d, seen  faintly), b 1 (Fig. 3g, seen faintly), b 2 (Fig. 3h) and b 3  (Fig. 3i) was found. Under the conditions of our experiment, we did not detect expression of the a 1A (Fig. 3a) , a 2B (Fig. 3e) or a 2C (Fig. 3f) receptors. As the pDMEC population contains a small number of non-EC contaminating cells, we also examined a transformed clonal murine microvascular EC line that is devoid of contaminating cells, bEnd.3 cells, for expression of adrenergic receptors. This line expressed the same spectrum of adrenergic receptors as seen with pDMECs, with the exception that we also found expression of the a 2C receptor (data not shown).
We similarly examined ECs derived from inguinal and axillary lymph nodes of BALB/c mice for expression of adrenergic receptors. Expression of a 1A (Fig. 4a) , a 1B (Fig. 4b), a 1D (Fig. 4c) , a 2A (Fig. 4d, seen faintly) , b 1 (Fig. 4g , seen faintly), b 2 ( Fig. 4h) and b 3 (Fig. 4i) was found. Under the conditions of our experiment, we did not detect expression of the a 1A (Fig. 4a), a 2B (Fig. 4e) or a 2C (Fig. 4f) receptors.
Regulatory effects of NE-treated pDMECs do not depend on cell-cell contact
To address the question of whether physical contact is necessary for the regulatory effects of NE-treated pDMECs, Transwell inserts were employed in additional experiments to separate ECs spatially from LCs and Tcells in experiments similar to those shown in Figs 1 and 2. Supernatants were harvested 48 hr later for measurement of cytokine content. As seen in the previous experiments, the production of IL-17A (Fig. 5a ) and IL-6 (Fig. 5b) was increased in wells containing NE-treated pDMECs while the production of IFN-c (Fig. 5c ) and IL-22 ( Fig. 5e) was decreased compared to that seen in wells with addition of medium-treated pDMECs. However, in this experiment a small but significant inhibition of IL-4 production was seen with the 10 À5 M NE concentration ( Fig. 5d ), suggesting that there may be a somewhat different regulation for IL-4 expression. We conclude that NE stimulates the release of a diffusible product that biases the result of antigen presentation by LCs to CD4 + T-cells. Under the conditions of our experiment, we did not detect expression of the a 1A , a 2B or a 2C receptors (note that the positive control in the gel for a1a shows two bands being amplified. This was expected with this primer pair, as it is known that two transcript variants would be amplified Pretreatment of pDMECs with siRNA to IL-6 prior to exposure to NE inhibited their ability to bias the outcome of antigen presentation
To investigate whether the effects of NE-treated pDMECs on the outcome of antigen presentation involved release of IL-6 by ECs, we treated pDMECs with IL-6 siRNA to knock down IL-6 production prior to treatment with NE and co-culture with LCs and T-cells. Again, experiments were performed as in Figs 1 and 2 . Compared to non-target siRNA-treated pDMECs, IL-6 siRNA-treated pDMECs without NE exposure significantly inhibited IL-17A (Fig. 6a ), IL-6 ( Fig. 6b) and (slightly) IL-22 (Fig. 6e) expression, but did not influence the production of IFN-c (Fig. 6c) or IL-4 (Fig. 6d) . Non-target siRNA-treated pDMECs exposed to NE led to a substantial increase in IL-17A (Fig. 6a ) and IL-6 (Fig. 6b) production, along with a significant decrease in IFN-c (Fig. 6c) and IL-22 ( Fig. 6e ) production compared to groups containing nontarget siRNA-treated pDMECs exposed to medium. IL-6 siRNA-treatment of pDMECs prior to exposure to NE abolished the increase in IL-17A (Fig. 6a ) and IL-6 ( Fig. 6b) production as well as the loss of the decrease in IFN-c (Fig. 6c ) and IL-22 ( Fig. 6e ) production observed in non-target siRNA-treated pDMECs exposed to NE. A very small but statistically significant increase in IL-4 expression was seen (Fig. 6d) . We conclude that IL-6 is a significant mediator of the effects of NE-exposure of pDMECs on the T-cell response to antigen presentation; however, we cannot exclude the involvement of other signalling molecules.
NE-exposed pDMECs bias the outcome of antigen presentation towards increased levels of mRNA for IL-17A and ROR-ct accompanied by decreased levels of IFN-c, IL-22 and T-bet
To investigate whether the effects reported occurred at a transcriptional level, we analysed the mRNA expression of each cytokine and specific transcription factors in T-cells.
In additional experiments set up in a manner similar to those described in Figs 1 and 2 , after 24 hr of culture Figure 6 . Interleukin (IL)-6 knock-down with small interfering RNA (siRNA) in primary dermal microvascular endothelial cells (pDMECs) inhibited the ability of norepinephrine (NE)-treated pDMECs to bias antigen presentation. pDMECs were cultured overnight with 100 nM mouse IL-6 siRNA or the corresponding non-targeting control siRNA. Cells were then stimulated with 1 9 10 À5 M NE or phosphate-buffered saline (PBS) alone for 3 hr. After extensive washing, Langerhans cells (LCs) and CD4 + T-cells from DO11.10 transgenic mice were added along with chicken ovalbumin (cOVA) 323-339, as described above. After 48 hr supernatants were assayed using enzyme-linked immunosorbent assay (ELISA). IL-6 siRNA-treatment of pDMECs prior to exposure to NE abolished the increase in (a) IL-17A and (b) IL-6 production as well as the loss of the decrease in (c) interferon (IFN)-c and (e) IL-22 production observed in wells containing non-target siRNA-treated pDMECs exposed to NE. A very small but statistically significant increase in (d) IL-4 expression; n = 3 independent experiments for all groups, mean AE standard deviation (SD); *P < 0Á05, ***P < 0Á001. non-adherent cells were removed from wells and LCs still bound to beads were removed by magnetic capture. Total RNA was extracted from the remaining cells (primarily T-cells) and IL-17A, IL-4, IFN-c and IL-22 mRNA levels were determined by RT-PCR. The presence of mediumtreated pDMECs during antigen presentation led to significantly enhanced levels of IL-17A (Fig. 7a), IFN-c  (Fig. 7b) and IL-22 (Fig. 7d) mRNA, while the IL-4 mRNA level showed no change (Fig. 7c) . The presence of NE-treated pDMECs during antigen presentation led to a much more substantial increase in IL-17A mRNA levels (Fig. 7a) , while the increases in IFN-c (Fig. 7b) and IL-22 (Fig. 7d ) mRNA levels were significantly inhibited. No change in the IL-4 mRNA level was seen (Fig. 7c) . Similarly, the level of mRNA for the transcription factor ROR-ct (associated with Th17 cell differentiation) was elevated in the presence of medium-treated pDMECs and more substantially and significantly elevated in the presence of NE-treated pDMECs (Fig. 7e) . The mRNA level of T-bet (associated with Th1 cell differentiation) was significantly elevated in the presence of medium-treated pDMECs, while the elevation was reversed in the presence of NE-treated pDMECs (Fig. 7f) . The level of mRNA for the transcription factor GATA3 (Th2 cells) was unchanged (Fig. 7g) .
NE-exposed pDMECs enhance differentiation of Tcells with intracellular IL-17A and reduce differentiation of T-cells with intracellular IFN-c or IL-4
FACS analysis of responding CD4
+ T-cells from cultures set up as above were performed as described in the Materials and methods section. After 48 hr of culture with PBS-or NE-pretreated pDMECs, CD4 + T-cells were harvested and examined by FACS analysis. Addition of medium-treated pDMECs to wells somewhat enhanced the proportions of cells producing IL-17A or IFN-c while slightly decreasing the IL-4-producing cells (a representative experiment is shown in Fig. 8a) . However, addition of NE-treated pDMECs further enhanced the number of IL-17A producing cells while the proportion of IFN-c-producing cells was greatly reduced and the proportion of IL-4-producing cells was further decreased (Fig. 8a) , although analysis of the combined results of four experiments demonstrated that the decrease in IL-4-expressing cells was not significant (see below). The mean percentages AE standard deviation (SD) of pDMECs expressing IL-17A, IFN-c or IL-4 in each treatment group were combined from five combined experiments for IL-17A and IFN-c and four combined experiments for IL-4 that demonstrated an increase in IL-17A-producing cells that did not quite reach statistical significance with the addition of pDMECs (P = 0Á053) (Fig. 8b) , that was further and significantly increased if the pDMECs were NE-treated (P < 0Á001) (Fig. 8b) ; a trend towards a decrease in IFN-cproducing cells was seen with the addition of pDMECs (P = 0Á118) (Fig. 8b) , that was further and significantly decreased if the pDMECs were NE-treated (P = 0Á014) (Fig. 8b) . IL-4-producing cells did not significantly change proportions, although a non-significant decrease was seen with the addition of pDMECs (P = 0Á069) and a small, further non-significant decrease was observed when pDMECs had been NE-treated (P = 0Á390).
Intradermal administration of NE biases the lymph node CD4
+ T-cell response to epicutaneous immunization towards an IL-17A response while inhibiting IFN-c, IL-22 and IL-4 responses
To determine whether NE can modulate the immune response in vivo, groups of BALB/c mice were injected intradermally with PBS containing NE or PBS alone. Fifteen minutes later, mice were immunized by topical application of dinitrofluorobenzene at sites of injection. Three days later, draining lymph nodes were harvested and a single cell suspension of CD4 + T-cell lymphocytes was prepared and stimulated in culture with anti-CD3 and anti-CD28. After 72 hr, supernatants were assayed Similarly, the level of mRNA for the transcription factor (e) ROR-ct was elevated in the presence of medium-treated pDMECs and more substantially and significantly elevated in the presence of NE-treated pDMECs. The mRNA level of (f) T-bet was significantly elevated in the presence of medium-treated pDMECs while the elevation was reversed in the presence of NE-treated pDMECs. The level of mRNA for the transcription factor (g) GATA3 was unchanged; n = 4 independent experiments (each of the four experiments demonstrated increased mRNA levels for IL-17, IL-6 and ROR-ct and decreased IFN-c, T-bet and IL-22 in cells cultured with NE-exposed pDMECs compared to cells cultured in unexposed pDMECs). Mean AE standard deviation (SD); ***P < 0Á001, **P < 0Á01, *P < 0Á05 compared to pDMECs without NE.
for cytokine content. Lymphocytes from mice treated with NE produced significantly more IL-17A but significantly less IFN-c, IL-22 and IL-4 compared with cells from control mice (Fig. 9 ). While this experiment does not identify which is the relevant target of NE in vivo, it is likely that NE is acting, at least in part, on ECs, allowing them to bias the results of antigen presentation.
Discussion
It is widely believed that stress alters cutaneous immunity 37, 38 and it is commonly believed to be a trigger for several inflammatory skin diseases. However, mechanisms responsible for these effects have remained incompletely understood. When individuals are exposed to stressors, the sympathetic nervous system can be activated leading to local secretion of catecholamines, especially NE, by sympathetic nerve termini. Catecholamines can bind to both a and b adrenergic receptors (ARs). ARs are G protein-coupled receptors and are subdivided into three classes: a1, a2 and b; each of which contains three members. b-ARs are widely expressed in cutaneous fibroblasts, keratinocytes and endothelial cells. [42] [43] [44] [45] As discussed in the Introduction section, ECs play key roles in inflammatory and immune reactions within the skin. Of course, there is much evidence that these functions are integral to the pathophysiology of inflammatory skin disorders. In this regard, as stated above, blood vessels and secondary lymphoid organs are innervated by both sensory and sympathetic nerves. [20] [21] [22] Thus, ECs are positioned for signalling from factors released by nerves. We now report that catecholamines, particularly NE, can influence antigen presentation in the skin through actions on ECs.
In this study, we have found that NE-exposed pDMECs bias the outcome of antigen presentation towards Th17/ IL-17-type immunity and away from Th1 responses. These results were confirmed at both mRNA and protein level. Th17 cells, named for their ability to produce IL-17A, have been characterized as a novel subset of CD4 + effector Th cells. 46 Th17 cells mediate inflammation and protect the host from invasion during pathogen infection. 47 However, dysregulated Th17 responses and IL-17A production have been associated with many chronic inflammatory diseases or autoimmune diseases, [48] [49] [50] [51] including psoriasis, 52 atopic dermatitis 53, 54 and certain other skin diseases. Indeed, systemic inhibition of IL-17A has been developed as an effective therapeutic for rheumatoid arthritis and psoriasis, 55, 56 although such treatment increases the risk of infection.
IL-6 has been reported to induce Th17 polarization in mice. 57 As shown above, NE-exposed pDMECs enhanced Th17 generation. In order to investigate the role of IL-6 in this effect, we used siRNA for IL-6 to block the IL-6 expression by pDMECs. The effect on the enhancement of IL-17A production was inhibited through the use of siRNA for IL-6. Thus, polarization of antigen presentation to CD4 + T-cells towards a Th17 response by NEexposed ECs appears to be mediated, at least in part, by IL-6.
Interestingly, we also discovered that NE-exposed ECs led to not only decreased production of IFN-c but also decreased production of IL-22. Our data are consistent with studies in which IL-22 production among CD4 + Tcells is more closely related to IFN-c than IL-17. 58, 59 Although IL-22 was originally described as a significant product of Th17 cells, it is also derived from activated Th1, natural killer cells and gamma delta T-cells. 60 In humans, a subset of CD4 + T-cells that specifically expresses IL-22 has been identified, termed Th22 cells. 61 IL-22 has predominant effects on epithelial cells, and it is thought to play a central role in inflammatory diseases, such as psoriasis. Its expression is massively increased both in the lesions 62 and serum 63 in psoriatic patients. Recent studies have indicated that human mast cells are major IL-22 producers in patients with psoriasis. 64 However, following a Phase 2 study, work on the use of an anti-IL-22 antibody for the treatment of psoriasis was apparently discontinued and, reportedly, results of the trial were not promising. 65, 66 Thus, NE may have a role in psoriatic inflammation through enhancement of IL-17A via effects on ECs.
It should also be noted that NE-exposed ECs yielded differing responses in our various assays for IL-4. No effect on CD4 + T-cell IL-4 cytokine release was seen in most experiments, nor were changes in mRNA levels for IL-4 observed in our in-vitro experiments. However, a small but significant decrease in IL-4 production was seen in Transwell experiments separating pDMECs from LCs and T-cells, intracellular IL-4-bearing T-cells were somewhat reduced by FACS analysis and pretreatment of pDMECs with siRNA led to a very small but significantly enhanced IL-4 release in cultures containing NE-treated pDMECs compared to wells containing non-target siRNA-treated pDMECs Thus, although a trend overall was seen towards reduced IL-4 expression in the presence of NE-treated pDMECs during the course of antigen presentation in vitro, the effect is small and it is unclear whether it is biologically significant. There was, however, a moderate IL-4 reduction seen in the in-vivo experiments. Of course, the in-vivo experiments do not define the cellular targets of NE and may involve the activation of multiple pathways. Nonetheless, other than IL-4, the results of the in-vivo experiments were similar to what we have seen in our in-vitro experiments.
ECs play a central role in cutaneous immunity and inflammation. First, given their location in the skin, they are in a position to sense a wide variety of stimuli and initiate an immune response. Secondly, ECs are able to amplify the inflammatory response by adhesion molecule expression, cytokine production and angiogenesis. Under some circumstances, particularly after exposure to IFN-c, ECs are able to function as APCs. 67, 68 Thus, in the presence of T-cells responding to antigen presentation by LCs, it could be considered that the milieu of the EC may induce them to become effective APCs. This highlights the importance of our Transwell experiments in which pDMECs were spatially separated from LCs and Tcells. The results of these experiments provide further evidence that our findings do not derive from the ECs acting as APCs and occur through the actions of a soluble mediator(s). Our results indicate that one of these mediators (and possibly the sole mediator) is IL-6.
Although NE is the classic and primary sympathetic neurotransmitter in the periphery, adrenomedullary EPI and NE may reach skin cells through the circulation. Furthermore, there are other sources of catecholamines in the skin. For example, epidermal keratinocytes are capable of producing both NE and EPI. 69, 70 We found that EPI was also capable of activating ECs to bias immune response towards an IL-17 response, but was less potent than NE.
Our findings demonstrate that NE has significant regulatory effects on the outcome of antigen presentation through actions on ECs. These data suggest that through release (or non-release) of NE from sympathetic nerves, the nervous system regulates the character and magnitude of Th cell immune responses. Under conditions of stress, release of NE by sympathetic nerves may bias immunity towards the Th17 pole through this pathway, with consequent exacerbation of disorders involving inappropriate or unwanted Th17-type immunity. Future experiments will determine the physiological, pathophysiological and therapeutic importance of these observations.
